Multisystem inflammatory syndrome in adults : Characteristics, treatment, and outcomes
Abstract Following the rapidly increasing number of multisystem inflammatory syndromes in children (MIS‐C), a similar clinical scenario has been observed in adult patients. Although its prevalence is low and probably related to underdiagnosis, its development can be associated with high mortality. Multisystem inflammatory syndrome in adults (MIS‐A) can develop following both asymptomatic and symptomatic severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and in previously healthy people. Like MIS‐C, MIS‐A is a multisystem disease that can involve the cardiovascular, respiratory, gastrointestinal, dermatologic, hematologic, and neurologic systems. In addition to the clinical manifestations, the diagnosis of MIS‐A requires laboratory evidence of inflammation and SARS‐CoV‐2 infection. The appropriate treatment for MIS‐A remains unclear; anti‐inflammatory agents, including intravenous immunoglobulin and corticosteroids, are commonly used. However, there are still many unknowns regarding MIS‐A. Further studies are needed to determine the true prevalence, pathogenesis, and effective treatment for MIS‐A..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Journal of Medical Virology - 95(2023), 2 |
| Beteiligte Personen: |
Lai, Chih‐Cheng [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 Wiley Periodicals LLC. |
|---|
| Umfang: |
9 |
|---|
| doi: |
10.1002/jmv.28426 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY016193229 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY016193229 | ||
| 003 | DE-627 | ||
| 005 | 20231111175729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/jmv.28426 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_JMV_2023_95_2.zip.xml |
| 035 | |a (DE-627)WLY016193229 | ||
| 035 | |a (WILEY)JMV28426 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Lai, Chih‐Cheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multisystem inflammatory syndrome in adults |b Characteristics, treatment, and outcomes |
| 264 | 1 | |c 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a Abstract Following the rapidly increasing number of multisystem inflammatory syndromes in children (MIS‐C), a similar clinical scenario has been observed in adult patients. Although its prevalence is low and probably related to underdiagnosis, its development can be associated with high mortality. Multisystem inflammatory syndrome in adults (MIS‐A) can develop following both asymptomatic and symptomatic severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and in previously healthy people. Like MIS‐C, MIS‐A is a multisystem disease that can involve the cardiovascular, respiratory, gastrointestinal, dermatologic, hematologic, and neurologic systems. In addition to the clinical manifestations, the diagnosis of MIS‐A requires laboratory evidence of inflammation and SARS‐CoV‐2 infection. The appropriate treatment for MIS‐A remains unclear; anti‐inflammatory agents, including intravenous immunoglobulin and corticosteroids, are commonly used. However, there are still many unknowns regarding MIS‐A. Further studies are needed to determine the true prevalence, pathogenesis, and effective treatment for MIS‐A. | ||
| 700 | 1 | |a Hsu, Chi‐Kuei |4 aut | |
| 700 | 1 | |a Hsueh, Shun‐Chung |4 aut | |
| 700 | 1 | |a Yen, Muh‐Yong |4 aut | |
| 700 | 1 | |a Ko, Wen‐Chien |4 aut | |
| 700 | 1 | |a Hsueh, Po‐Ren |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Medical Virology |g 95(2023), 2 |w (DE-627)WLY008980918 |x 10969071 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2023 |g number:2 |g extent:9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2023 |e 2 |g 9 | ||